NASDAQ:OSA ProSomnus (OSA) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free OSA Stock Alerts $0.20 +0.08 (+67.80%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.14▼$0.2050-Day Range$0.15▼$0.7452-Week Range$0.35▼$5.25Volume52,665 shsAverage Volume65,686 shsMarket Capitalization$3.44 millionP/E RatioN/ADividend YieldN/APrice Target$2.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get ProSomnus alerts: Email Address ProSomnus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,078.5% Upside$2.33 Price TargetShort InterestHealthy1.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.35 out of 5 stars 3.3 Analyst's Opinion Consensus RatingProSomnus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProSomnus has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.18% of the float of ProSomnus has been sold short.Short Interest Ratio / Days to CoverProSomnus has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProSomnus has recently decreased by 39.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProSomnus does not currently pay a dividend.Dividend GrowthProSomnus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OSA. Previous Next 2.3 News and Social Media Coverage News SentimentProSomnus has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ProSomnus this week, compared to 1 article on an average week.Search Interest3 people have searched for OSA on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProSomnus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of ProSomnus is held by insiders.Percentage Held by Institutions70.03% of the stock of ProSomnus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ProSomnus is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProSomnus is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About ProSomnus Stock (NASDAQ:OSA)ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.Read More OSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OSA Stock News HeadlinesApril 21, 2024 | americanbankingnews.comContrasting ProSomnus (NASDAQ:OSA) and Cytosorbents (NASDAQ:CTSO)April 20, 2024 | finance.yahoo.comProSomnus, Inc. (OSA) Interactive Stock Chart - Yahoo FinanceApril 23, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.April 17, 2024 | msn.comProSomnus (OSA) Price Target Increased by 38.89% to 2.55April 17, 2024 | americanbankingnews.comContrasting ProSomnus (OSA) and Its CompetitorsApril 15, 2024 | americanbankingnews.comComparing ProSomnus (OSA) & Its CompetitorsApril 15, 2024 | americanbankingnews.comHead-To-Head Review: ProSomnus (OSA) and The CompetitionMarch 31, 2024 | finanznachrichten.deProSomnus Sleep Technologies, Inc.: ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial ResultsApril 23, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.March 30, 2024 | finance.yahoo.comProSomnus, Inc. Common Stock (NASDAQ:OSA) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | investorplace.comOSA Stock Earnings: ProSomnus Misses EPS, Beats Revenue for Q4 2023March 27, 2024 | finance.yahoo.comQ4 2023 Prosomnus Inc Earnings CallMarch 26, 2024 | globenewswire.comProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 15, 2024 | globenewswire.comProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update CallFebruary 23, 2024 | msn.comProSomnus reports pilot study data for remote OSA monitoring deviceFebruary 23, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)February 22, 2024 | finance.yahoo.comProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep ApneaFebruary 22, 2024 | globenewswire.comProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep ApneaFebruary 20, 2024 | finance.yahoo.comProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024January 30, 2024 | finance.yahoo.comProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDAJanuary 29, 2024 | finance.yahoo.comProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA DevicesJanuary 23, 2024 | benzinga.comProSomnus Stock (NASDAQ:OSA) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep ApneaDecember 20, 2023 | morningstar.comProSomnus Inc OSADecember 19, 2023 | msn.comWhy Is Sleep Devices Focused ProSomnus Stock Soaring Today?December 19, 2023 | finance.yahoo.comProSomnus Treatment for Sleep Apnea Effective, Study ShowsDecember 19, 2023 | finance.yahoo.comData Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance DevicesSee More Headlines Receive OSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProSomnus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:OSA CUSIPN/A CIK1934064 Webwww.ProSomnus.com Phone844-537-5337FaxN/AEmployees136Year FoundedN/APrice Target and Rating Average Stock Price Target$2.33 High Stock Price Target$4.00 Low Stock Price Target$1.00 Potential Upside/Downside+1,078.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,090,000.00 Net Margins-87.14% Pretax Margin-87.14% Return on EquityN/A Return on Assets-106.30% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio0.86 Sales & Book Value Annual Sales$27.65 million Price / Sales0.12 Cash FlowN/A Price / Cash FlowN/A Book Value($2.33) per share Price / Book-0.08Miscellaneous Outstanding Shares17,394,000Free Float16,055,000Market Cap$3.44 million OptionableNot Optionable Beta0.21 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Leonard Liptak (Age 49)Co-Founder, CEO & Director Comp: $965.35kMr. Sung Kim (Age 42)Co-Founder & CTO Comp: $454.63kMs. Laing F. RikkersCo-founder & Executive ChairmanMr. Brian B. Dow (Age 55)CFO & Corporate Secretary Dr. John E. Remmers M.D.Chief ScientistMs. Heather WhalenVice President of Global Marketing ServicesDr. Shouresh Charkhandeh D.D.S.Global Scientific Committee ChairMore ExecutivesKey CompetitorsVapothermNYSE:VAPOIntelligent Bio SolutionsNASDAQ:INBSBIOLASENASDAQ:BIOLAdial PharmaceuticalsNASDAQ:ADILAkari TherapeuticsNASDAQ:AKTXView All CompetitorsInstitutional OwnershipAxxcess Wealth Management LLCBought 21,700 shares on 2/6/2024Ownership: 0.193%View All Institutional Transactions OSA Stock Analysis - Frequently Asked Questions Should I buy or sell ProSomnus stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProSomnus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OSA shares. View OSA analyst ratings or view top-rated stocks. What is ProSomnus' stock price target for 2024? 3 analysts have issued 12-month target prices for ProSomnus' stock. Their OSA share price targets range from $1.00 to $4.00. On average, they anticipate the company's share price to reach $2.33 in the next twelve months. This suggests a possible upside of 1,078.5% from the stock's current price. View analysts price targets for OSA or view top-rated stocks among Wall Street analysts. How have OSA shares performed in 2024? ProSomnus' stock was trading at $0.9802 at the beginning of the year. Since then, OSA shares have decreased by 79.8% and is now trading at $0.1980. View the best growth stocks for 2024 here. Are investors shorting ProSomnus? ProSomnus saw a decline in short interest in March. As of March 31st, there was short interest totaling 73,900 shares, a decline of 39.9% from the March 15th total of 123,000 shares. Based on an average trading volume of 66,700 shares, the short-interest ratio is currently 1.1 days. Currently, 1.2% of the shares of the stock are sold short. View ProSomnus' Short Interest. When is ProSomnus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our OSA earnings forecast. How do I buy shares of ProSomnus? Shares of OSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OSA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProSomnus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
